-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Maintains Buy on Nurix Therapeutics, Raises Price Target to $36

Benzinga·10/16/2026 10:13:53
语音播报
HC Wainwright & Co. analyst Robert Burns maintains Nurix Therapeutics (NASDAQ:NRIX) with a Buy and raises the price target from $34 to $36.